NorthWest Biotherapeutics Inc (NWBO)

[LearningEveryTrade]

The original primary endpoint, when the trial was designed in 2007, was progression-free survival (PFS); while the trial was underway, pseudo-progression (PsPD) became recognized as major issue -- difficulty distinguishing real vs. PsPD. So, the statistical analysis plan focused on overall survival (OS), and specified OS as the primary endpoint before unblinding.

Trial est complete date Nov 2022, per clinicaltrails.gov.